Anthony T. Reder

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin et al. · The Lancet Neurology · 2014 · 815 citations

Disease Management, Relapsing-remitting Multiple Sclerosis, Disease Progression +7

Neuro-QOL

David Cella, Jin‐Shei Lai, Cindy J. Nowinski et al. · Neurology · 2012 · 736 citations · Full text

Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument

David Cella, Kelly K. Dineen, B. G. W. Arnason et al. · Neurology · 1996 · 404 citations

Brief International Cognitive Assessment for MS (BICAMS): international standards for validation

Ralph H. B. Benedict, Maria Pia Amato, Jan Boringa et al. · BMC Neurology · 2012 · 403 citations · Full text

Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis

Davide Maimone, Susan A. Gregory, Barry G.W. Arnason et al. · Journal of Neuroimmunology · 1991 · 330 citations

Inflammation, Cytokine Levels, Autoimmune Disease +9